Charlie Holst, PhD

VP and Head of Biology

Since the age of 12, when he lost his grandmother to lymphoma, Charlie has been driven to understand the pathological underpinnings of disease and dedicated to finding more effective and targeted drugs to reduce human suffering. With over 20 years’ background in drug discovery and development in roles of increasing responsibility at Genentech, Exelixis, Pfizer, PTC, and Ribometrix, Charlie brings extensive experience, passion, and leadership to Ten63. He has contributed to the advancement of both small and large molecule drugs, in diverse therapeutic areas, including oncology, immunology/inflammation, and neuroscience.

Charlie earned his PhD in Cell Biology as a Howard Hughes Pre-doctoral Fellow at UCSF, studying early epigenetic alterations in breast cancer, and as a Goldwater Scholar, graduated summa cum laude with a BA in Biology from Lawrence University. He lives in Cary with his family and rescue dog, Bailey. When not at work, Charlie enjoys baking, fencing, and hiking.